查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1756412

疼痛管理治疗市场，按疼痛类型、药物类别、给药途径、最终用户、国家和地区划分 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Pain Management Therapeutics Market, By Type of Pain, By Drug Class, By Administration Route, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 398 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年疼痛管理治疗市场规模价值为 849.78 亿美元，2025 年至 2032 年的复合年增长率为 3.78%。

推动这一市场发展的因素包括慢性病盛行率上升、人口老化以及人们对疼痛管理方案的认识不断提高。药物配方和给药方式的创新也扩大了治疗的可能性。此外，对非成瘾性、更安全的止痛替代品的需求日益增长，也正在塑造市场趋势。此领域涵盖与癌症、关节炎、神经病变和术后恢復相关的疼痛。总而言之，它透过解决全球最常见且最具挑战性的疼痛症状之一，在医疗保健领域发挥着至关重要的作用。

疼痛管理治疗市场-市场动态

对非鸦片类止痛药的需求不断增长，推动了更安全的治疗替代方案的出现。

非鸦片类止痛药需求的不断成长是疼痛管理治疗市场的重要驱动力。对鸦片类药物成瘾、滥用和副作用的担忧促使患者和医疗保健提供者寻求更安全的替代方案。非鸦片类药物疗法，包括非类固醇抗发炎药、抗惊厥药、抗忧郁药和局部治疗，能有效缓解疼痛，且风险较低。

这一转变得益于全球范围内日益增多的认知宣传活动以及对阿片类药物处方更严格的监管。此外，研究的进步也催生了能够更精准地靶向疼痛机制的创新非鸦片类药物。因此，市场正在扩大其产品组合，以纳入这些更安全的选择。这一趋势在慢性疼痛治疗​​中尤其重要，因为长期使用鸦片类药物往往会带来问题。总体而言，对非鸦片类药物的需求正在重塑治疗方法，并加速市场成长。

疼痛管理治疗市场—关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 3.78%。

根据疼痛类型细分，慢性疼痛预计在 2024 年占据最大市场份额

根据药物类别细分，阿片类药物是 2024 年领先的药物类别

根据给药途径细分，口服是 2024 年领先的通路

根据最终用户细分，医院是 2024 年的主要分销管道

按地区划分，北美是 2024 年的主要收入来源

疼痛管理治疗市场-細項分析：

全球疼痛管理治疗市场根据疼痛类型、药物类别、分布、最终用户和地区进行细分。

依疼痛类型，市场分为五类：急性疼痛、慢性疼痛、癌症疼痛、神经性疼痛、术后疼痛。慢性疼痛由于其普遍性和长期性，在疼痛管理治疗市场中占据主导地位。与暂时性且与损伤或手术有关的急性疼痛不同，慢性疼痛会持续数月或数年，通常由关节炎、神经病变或纤维肌痛等疾病引起。慢性疼痛的管理具有挑战性，因为它会严重影响患者的生活品质和日常功能。这导致对有效且可持续的疼痛缓解疗法的需求日益增长。全球老龄人口和慢性病病例的增加进一步推动了对慢性疼痛的创新疗法的需求。

依药物类别，市场可分为五类：鸦片类药物、非鸦片类止痛药、辅助性止痛药、局部止痛药、其他。阿片类药物因其在缓解中度至重度疼痛方面的强大功效，仍然是疼痛管理治疗市场中的主导药物类别。它们透过与大脑和脊髓中的鸦片受体结合，显着降低痛觉。儘管阿片类药物疗效显着，但由于对成瘾性和副作用的担忧，其使用受到监管加强，并趋于谨慎。然而，阿片类药物仍然被广泛使用，尤其是在癌症疼痛和术后疼痛管理方面。更安全的鸦片类药物製剂的持续开发旨在平衡疼痛缓解与风险最小化，从而保持其在疼痛治疗中的关键地位。

疼痛管理治疗市场-地理洞察

北美地区凭藉其完善的医疗基础设施和较高的慢性疼痛盛行率，在疼痛管理治疗市场中占据主导地位。美国引领市场，主要原因是其老化人口中关节炎、癌症和神经性疼痛病例的增加。此外，人们对疼痛管理方案的认识不断提高，以及先进疗法的广泛应用也促进了市场的成长。该地区的监管机构正在推广更安全的疼痛管理实践，这加速了向非鸦片类药物替代品的转变。

美国是北美疼痛管理治疗市场的最大贡献者，这得益于慢性疼痛疾病的高发性和人口老化。人们对鸦片类药物成瘾的认识不断提高，推动了对更安全的非鸦片类止痛药的需求。强大的医疗基础设施、先进的研究以及政府对疼痛管理的支持措施进一步增强了市场的成长。领先製药公司的入驻也促进了疼痛治疗领域的持续创新。

疼痛管理治疗市场-竞争格局：

疼痛管理治疗市场的竞争格局瞬息万变，领先的製药和生技公司之间竞争激烈。主要参与者专注于产品创新、策略合作和收购，以巩固其市场地位。各公司正大力投资研发，以创造更安全、更有效的疼痛缓解方案，尤其是非鸦片类药物疗法，以满足不断变化的监管要求和患者偏好。

市场也见证了基于药物配方、给药技术和定价策略的竞争。拥有创新治疗方案的新兴企业正在挑战老牌企业，推动进一步的创新。此外，各公司正在透过合作和授权协议扩大其地域覆盖范围。持续的鸦片类药物危机促使各公司加速开发替代性疼痛管理疗法，加剧了市场竞争。总体而言，这种竞争环境促进了持续的进步，使全球患者和医疗保健提供者受益。

最新动态：

2025年1月，Vertex Pharmaceuticals公司获得FDA核准，其新药Journavx（舒泽三嗪）用于治疗中度至重度急性疼痛。这是二十多年来首个核准的新型止痛药。 Journavx标靶作用于痛觉神经元特异的钠通道，有效缓解疼痛，且不具备鸦片类药物的成瘾性。此次批准标誌着非阿片类疼痛治疗领域取得重大进展。

目录

第一章：疼痛管理治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 疼痛管理治疗市场片段（依疼痛类型划分）
    • 疼痛管理治疗市场（依药物类别）
    • 疼痛管理治疗市场依给药途径划分
    • 疼痛管理治疗市场片段（按最终用户）
    • 疼痛管理治疗市场（按国家/地区）
    • 疼痛管理治疗市场（按地区）
  • 竞争洞察

第三章：疼痛管理治疗的关键市场趋势

  • 疼痛管理治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 疼痛管理治疗市场的限制
    • 市场限制的影响分析
  • 疼痛管理治疗市场机会
  • 疼痛管理治疗市场未来趋势

第四章：疼痛管理治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：疼痛管理治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：疼痛管理治疗市场格局

  • 2024年疼痛管理治疗市场占有率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：疼痛管理治疗市场－按疼痛类型

  • 概述
    • 依疼痛类型分析细分市场份额
    • 急性疼痛
    • 慢性疼痛
    • 癌症痛
    • 神经性疼痛
    • 术后疼痛

第 8 章：疼痛管理治疗市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 阿片类药物
    • 非鸦片类镇痛药
    • 辅助止痛药
    • 局部止痛药
    • 其他的

第九章：疼痛管理治疗市场－依给药途径

  • 概述
    • 按管理途径分類的细分市场占有率分析
    • 口服
    • 注射剂
    • 透皮
    • 外用

第 10 章：疼痛管理治疗市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 门诊手术中心
    • 居家照护环境
    • 其他的

第 11 章：疼痛管理治疗市场 - 按地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美疼痛管理治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按疼痛类型）
    • 北美市场规模及预测（依药品类别）
    • 北美市场规模及预测（依行政路线）
    • 北美市场规模及预测（按最终用户）
    • 美国
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲疼痛管理治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按疼痛类型）
    • 欧洲市场规模及预测（依药品类别）
    • 欧洲市场规模及预测（依行政路线）
    • 欧洲市场规模及预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区疼痛管理治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区疼痛市场规模及预测（依疼痛类型）
    • 亚太地区市场规模及预测（依药品类别）
    • 亚太地区市场规模及预测（依行政路线）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲疼痛管理治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依疼痛类型划分）
    • 拉丁美洲市场规模及预测（依药品类别）
    • 拉丁美洲市场规模及预测（依管理途径）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲疼痛管理治疗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依疼痛类型）
    • MEA 市场规模及预测（依药物类别）
    • MEA 市场规模及预测（依管理途径）
    • MEA 市场规模及预测（依最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-疼痛管理治疗产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Johnson & Johnson
    • Pfizer Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Novartis AG
    • Grunenthal GmbH
    • Mylan NV
    • Mallinckrodt Pharmaceuticals
    • Sanofi SA
    • Allergan (AbbVie)
    • AstraZeneca plc
    • Endo International plc
    • Bristol-Myers Squibb
    • Bayer AG
    • AcelRx Pharmaceuticals

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5318

REPORT HIGHLIGHT

Pain Management Therapeutics Market size was valued at US$ 84,978 Million in 2024, expanding at a CAGR of 3.78% from 2025 to 2032.

The Pain Management Therapeutics Market focuses on treatments and medications designed to relieve or reduce pain caused by various medical conditions. This market includes a wide range of products such as opioids, non-opioid analgesics, anti-inflammatory drugs, topical agents, and advanced therapies like nerve blocks and neuromodulation. The primary goal is to improve patient quality of life by managing acute and chronic pain effectively.

Factors driving this market include the rising prevalence of chronic diseases, an aging population, and increasing awareness about pain management options. Innovations in drug formulations and delivery methods are also expanding therapeutic possibilities. Additionally, the growing demand for non-addictive and safer pain relief alternatives is shaping market trends. The sector covers pain related to cancer, arthritis, neuropathic conditions, and postoperative recovery. Overall, it plays a critical role in healthcare by addressing one of the most common and challenging symptoms experienced worldwide.

Pain Management Therapeutics Market- Market Dynamics

Rising demand for non-opioid pain relief fuels safer therapeutic alternatives.

The rising demand for non-opioid pain relief is a significant driver in the Pain Management Therapeutics Market. Concerns over opioid addiction, abuse, and side effects have pushed both patients and healthcare providers to seek safer alternatives. Non-opioid therapies, including NSAIDs, anticonvulsants, antidepressants, and topical treatments, offer effective pain relief with lower risk profiles.

This shift is supported by growing awareness campaigns and stricter regulations on opioid prescriptions worldwide. Additionally, advancements in research are producing innovative non-opioid drugs that target pain mechanisms more precisely. As a result, the market is expanding its portfolio to include these safer options. This trend is especially important in managing chronic pain conditions, where long-term opioid use is often problematic. Overall, the demand for non-opioid therapies is reshaping treatment approaches and accelerating market growth.

Pain Management Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.78% over the forecast period (2025-2032)

Based on Type of Pain segmentation, Chronic Pain was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, Opioids was the leading Drug Class in 2024

Based on Administration Route segmentation, Oral was the leading distribution in 2024

Based on end-user segmentation, Hospitals was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pain Management Therapeutics Market- Segmentation Analysis:

The Global Pain Management Therapeutics Market is segmented on the basis of Type of Pain, Drug Class, Distribution, End-user, and Region.

The market is divided into five categories based on Type of Pain: Acute Pain, Chronic Pain, Cancer Pain, Neuropathic Pain, Postoperative Pain. Chronic pain is the dominant segment in the Pain Management Therapeutics Market due to its widespread prevalence and long-lasting nature. Unlike acute pain, which is temporary and linked to injury or surgery, chronic pain persists for months or years, often resulting from conditions like arthritis, neuropathy, or fibromyalgia. Managing chronic pain is challenging because it significantly affects patients' quality of life and daily functioning. This has led to a growing demand for effective and sustainable pain relief therapies. The rising number of aging populations and chronic disease cases worldwide further drive the need for innovative treatments targeting chronic pain.

The market is divided into five categories based on Drug Class: Opioids, Non-Opioid Analgesics, Adjuvant Analgesics, Topical Analgesics, Others. Opioids remain the dominant drug class in the Pain Management Therapeutics Market due to their strong effectiveness in relieving moderate to severe pain. They work by binding to opioid receptors in the brain and spinal cord, significantly reducing pain perception. Despite their high efficacy, concerns over addiction and side effects have led to increased regulation and cautious use. However, opioids continue to be widely prescribed, especially for cancer pain and postoperative pain management. The ongoing development of safer opioid formulations aims to balance pain relief with minimizing risks, maintaining their key role in pain therapeutics.

Pain Management Therapeutics Market- Geographical Insights

The North American region holds a dominant position in the Pain Management Therapeutics Market due to its well-established healthcare infrastructure and high prevalence of chronic pain conditions. The United States leads the market, driven by increasing cases of arthritis, cancer, and neuropathic pain among its aging population. Additionally, growing awareness about pain management options and widespread adoption of advanced therapies contribute to market growth. Regulatory agencies in the region are promoting safer pain management practices, which has accelerated the shift toward non-opioid alternatives.

The United States is the largest contributor to the Pain Management Therapeutics Market within North America, driven by a high prevalence of chronic pain conditions and an aging population. Increased awareness about opioid addiction has boosted demand for safer, non-opioid pain relief options. Robust healthcare infrastructure, advanced research, and government initiatives supporting pain management further strengthen market growth. The presence of leading pharmaceutical companies also fosters continuous innovation in pain therapeutics.

Pain Management Therapeutics Market- Competitive Landscape:

The competitive landscape of the Pain Management Therapeutics Market is highly dynamic and characterized by intense rivalry among leading pharmaceutical and biotech companies. Key players focus on product innovation, strategic partnerships, and acquisitions to strengthen their market positions. Companies are investing heavily in research and development to create safer and more effective pain relief options, particularly non-opioid therapies, to meet changing regulatory requirements and patient preferences.

The market also witnesses competition based on drug formulations, delivery technologies, and pricing strategies. Emerging players with novel therapeutic solutions are challenging established firms, driving further innovation. Additionally, companies are expanding their geographic presence through collaborations and licensing agreements. The ongoing opioid crisis has pushed companies to accelerate development of alternative pain management therapies, increasing market competition. Overall, this competitive environment fosters continuous advancements that benefit patients and healthcare providers worldwide.

Recent Developments:

In January 2025, Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a novel non-opioid painkiller for moderate-to-severe acute pain. This marks the first approval of a new class of pain medication in over two decades. Journavx targets sodium channels specific to pain neurons, offering effective pain relief without the addictive potential of opioids. The approval signifies a significant advancement in non-opioid pain management options.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Grunenthal GmbH
  • Mylan N.V.
  • Mallinckrodt Pharmaceuticals
  • Sanofi S.A.
  • Allergan (AbbVie)
  • AstraZeneca plc
  • Endo International plc
  • Bristol-Myers Squibb
  • Bayer AG
  • AcelRx Pharmaceuticals

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY TYPE OF PAIN- MARKET ANALYSIS, 2019 - 2032

  • Acute Pain
  • Chronic Pain
  • Cancer Pain
  • Neuropathic Pain
  • Postoperative Pain

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Opioids
  • Non-Opioid Analgesics
  • Adjuvant Analgesics
  • Topical Analgesics
  • Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal
  • Topical

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pain Management Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pain Management Therapeutics Market Snippet by Type of Pain
    • 2.1.2. Pain Management Therapeutics Market Snippet by Drug Class
    • 2.1.3. Pain Management Therapeutics Market Snippet by Administration Route
    • 2.1.4. Pain Management Therapeutics Market Snippet by End-user
    • 2.1.5. Pain Management Therapeutics Market Snippet by Country
    • 2.1.6. Pain Management Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Pain Management Therapeutics Key Market Trends

  • 3.1. Pain Management Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pain Management Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pain Management Therapeutics Market Opportunities
  • 3.4. Pain Management Therapeutics Market Future Trends

4. Pain Management Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pain Management Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pain Management Therapeutics Market Landscape

  • 6.1. Pain Management Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pain Management Therapeutics Market - By Type of Pain

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Pain, 2024 & 2032 (%)
    • 7.1.2. Acute Pain
    • 7.1.3. Chronic Pain
    • 7.1.4. Cancer Pain
    • 7.1.5. Neuropathic Pain
    • 7.1.6. Postoperative Pain

8. Pain Management Therapeutics Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Opioids
    • 8.1.3. Non-Opioid Analgesics
    • 8.1.4. Adjuvant Analgesics
    • 8.1.5. Topical Analgesics
    • 8.1.6. Others

9. Pain Management Therapeutics Market - By Administration Route

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Administration Route, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Transdermal
    • 9.1.5. Topical

10. Pain Management Therapeutics Market - By End-user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Ambulatory Surgical Centers
    • 10.1.4. Home Care Settings
    • 10.1.5. Others

11. Pain Management Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Pain Management Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.8. The U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Pain Management Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Pain Management Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Pain Management Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Pain Management Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pain Management Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Johnson & Johnson
    • 12.2.2. Pfizer Inc.
    • 12.2.3. AbbVie Inc.
    • 12.2.4. Teva Pharmaceutical Industries Ltd.
    • 12.2.5. Eli Lilly and Company
    • 12.2.6. Novartis AG
    • 12.2.7. Grunenthal GmbH
    • 12.2.8. Mylan N.V.
    • 12.2.9. Mallinckrodt Pharmaceuticals
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Allergan (AbbVie)
    • 12.2.12. AstraZeneca plc
    • 12.2.13. Endo International plc
    • 12.2.14. Bristol-Myers Squibb
    • 12.2.15. Bayer AG
    • 12.2.16. AcelRx Pharmaceuticals

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us